Table 8.

Result of matching between the associations predicted by LP-HCLUS and those present in MNDR

ncRNA	Disease	LP-HCLUS	MNDR
h19	adenocarcinoma	0.7455674	s: 0.7311
h19	adrenocortical carcinoma	0.8150848	s: 0.7311
h19	aortic valve disease	0.6492379	s: 0.7311
h19	astrocytoma	0.7455674	s: 0.7311
h19	breast adenocarcinoma	0.7005121	s: 0.7311
h19	carcinoma, non-small-cell lung	0.7052352	s: 0.9820, p: 0.1097
h19	chronic myeloid leukemia	0.7005121	s: 0.8808
h19	colon carcinoma	0.7005121	s: 0.8589
h19	colorectal cancer	0.8150848	s: 0.9820, p: 0.1097
h19	coronary artery disease	0.6600133	w: 0.4752
h19	embryonal carcinoma	0.6522726	s: 0.9526
h19	endometriosis	0.7052352	s: 0.8808
h19	esophageal cancer	0.8150848	s: 0.8589
h19	gallbladder cancer	0.6522726	s: 0.8808
h19	heart defects, congenital	0.6703589	s: 0.8589
h19	laryngeal squamous cell carcinoma	0.6522726	s: 0.9526
h19	liver neoplasms	1.0000000	w: 0.4752
h19	lung adenocarcinoma	0.6669160	s: 0.8589
h19	lymphoma	0.6962170	p: 0.1321
h19	osteoarthritis	0.6749659	w: 0.4752
h19	osteosarcoma	0.7732385	s: 0.9820
h19	ovarian neoplasms	0.7052352	s: 0.8589, p: 0.1097
h19	pancreatic cancer	0.8150848	s: 0.8808
h19	pancreatic ductal adenocarcinoma	0.6575157	s: 0.9526
h19	polycythemia vera	0.7005121	s: 0.7311
h19	prostatic neoplasms	0.7052352	s: 0.7311, p: 0.1097
h19	rheumatoid arthritis	0.6703589	s: 0.9526
h19	schizophrenia	0.7052352	p: 0.1097
h19	squamous cell carcinoma	0.6826756	w: 0.4752
h19	thyroid cancer	0.7732385	s: 0.8808, p: 0.1097
h19	urinary bladder neoplasms	0.6962170	p: 0.1097
h19	uterine cervical neoplasms	0.7455674	s: 0.7311, p: 0.1097

MNDR scores are associated with an evidence type: s: strong experimental evidence, w: weak experimental evidence, p: prediction